Seeking Alpha

Stereotaxis shares surge following trial completion

  • Stereotaxis (STXS) shares storm 37% higher after the company says that it's completed a 120-patient FDA trial for one of its cardiology navigation products - the Vdrive Robotic Navigation System with V-Loop Circular Catheter Manipulator.
  • The Vdrive with V-Loop system is designed for "remotely controlling the advancement, retraction, rotation, tip deflection, and loop size of a compatible catheter," Stereotaxis says. (PR)
Comments (1)
  • Envoy Global Research
    , contributor
    Comments (431) | Send Message
    The company completed a trial and is submitting this to the FDA for approval. Nothing really extraordinary. The stock reacts as if the product actually got approval, though I'm certain the company is hoping enough investors mistake a trial completion for FDA approval, as STXS is looking to sell more equity as per recent filings.
    7 Jan, 09:24 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector